Status:
RECRUITING
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
Lead Sponsor:
Tata Memorial Centre
Conditions:
Medulloblastoma, WNT-activated
Eligibility:
All Genders
3-16 years
Phase:
NA
Brief Summary
This clinical study is going to be done on a type of brain tumor in children called Medulloblastoma. The WNT pathway type of medulloblastoma is considered to be low risk and have the best outcomes in ...
Detailed Description
WNT pathway medulloblastomas have the best prognosis amongst all four subgroups with 5-year overall survival exceeding 90%. Overall medulloblastoma is more common in males. They can occur at all ages,...
Eligibility Criteria
Inclusion
- Age more than 3 years and less than 16 years.
- Newly diagnosed WNT pathway medulloblastoma.
- Post-surgery residual disease less than 1.5 cm2 on post-operative MRI brain.
- No evidence of metastatic disease in the brain, spine or cerebral spinal fluid (CSF) assessed by MRI of the brain/spine and lumbar puncture for CSF cytology.
- Fit for initiation of adjuvant treatment within 6-weeks of surgery
Exclusion
- Age Less than 3 and more than 16 years.
- Molecular subgroup other than WNT pathway.
- Post-surgery residual disease more than 1.5cm2 on post-operative imaging.
- Evidence of any metastatic disease in the brain, spine or CSF.
- Previous history of radiotherapy or chemotherapy prior to study enrollment.
- Not fit for initiation of adjuvant treatment within 6 weeks of surgery.
- Not willing for consent/assent.
Key Trial Info
Start Date :
August 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2030
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04474964
Start Date
August 13 2020
End Date
July 1 2030
Last Update
April 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tata Memorial Hospital
Mumbai, Maharashtra, India, 400012